Close-up of an the ICR logo on a research centre

Centre for In Vivo Modelling

The Centre for In Vivo Modelling is a newly established research centre within the Division of Cancer Biology at the ICR. Our scientists and clinical researchers use state-of-the-art in vivo models to address fundamental questions in cancer biology, with the ultimate aim of identifying curative treatments. We also serve as a collaborative hub across the ICR and The Royal Marsden, providing cutting-edge expertise in advanced mouse genetics and humanised in vivo models of cancer.

Professor Kamil R Kranc, Chair of Haemato-Oncology, serves as the Centre's Director, while Fabiana Muzzonigro is the Centre Administrator.

 

How we conduct research at this centre

Solid tumours and blood cancers are highly complex ecosystems, with many composed of varying cell types including rare cancer stem cells at the apex of a hierarchical organisation, more differentiated malignant progeny, and a dynamic microenvironment that nurtures tumour growth and survival. At our Centre, we seek to elucidate the fundamental principles that govern this malignant ecosystem. We employ advanced mouse genetics (including barcoding and lineage tracing) and PDX models to dissect how tumour cells function, evolve under selective pressures, evade therapy, and engage with their microenvironment to sustain disease progression. By decoding these intricate cellular and molecular interactions, we aim to identify transformative therapeutic strategies capable of eradicating cancer at its origin - achieving durable remission while preserving normal tissue integrity.

A particular strength of our Centre lies in the generation and application of in vivo models, which are essential for uncovering novel aspects of cancer biology and evaluating emerging therapies. We work in close collaboration with ICR researchers and clinicians at The Royal Marsden to develop patient-derived xenograft (PDX) models of leukaemias and solid tumours by transplanting human cancer tissue into immunocompromised mice. In parallel, we generate and utilise genetically engineered mouse models (GEMMs) to interrogate cancer biology in a physiologically relevant context. By leveraging these sophisticated in vivo systems, the Centre aims to:

  • Uncover new facets of cancer biology in a complex in vivo ecosystem
  • Discover and validate novel therapeutic targets allowing for elimination of cancer stem cells and their malignant progeny in blood cancers and solid tumours
  • Collaborate closely with drug discovery teams at the ICR to develop inhibitors of these targets
  • Evaluate new anti-cancer drugs in pre-clinical in vivo models, paving the way for clinical trials.

In addition to our academic focus, CIVM serves as a collaborative hub across the ICR and The Royal Marsden, providing the ICR community with cutting-edge expertise in advanced mouse genetics and humanised mouse models of cancer.

Join us

We are recruiting two exceptional Group Leaders to join the Division of Cancer Biology and the Centre for In Vivo Modelling (CIVM). This is a unique opportunity to shape the future of cancer biology research, lead innovative programmes, and make discoveries that transform patient outcomes.

These new Group Leaders will investigate fundamental mechanisms of tumour initiation, progression, and treatment resistance, and develop cutting-edge preclinical models to advance understanding of cancer biology. Working in close collaboration across the ICR and The Royal Marsden Hospital, the postholders will translate discovery science into new therapeutic opportunities, contributing to the ICR’s mission to make the discoveries that defeat cancer.

Find out more about the vacancies

Members of this Centre

Pipettes and well plates

In Vivo Modelling core

We provide cutting-edge expertise in advanced mouse genetics and humanized mouse models of cancer.

CIVM Service Core

Other staff:

Driving discovery through collaboration 

At CIVM, our collaborative spirit drives our mission to advance cancer cures. We actively partner with basic science, translational, and clinical research groups across the ICR and The Royal Marsden. Our collaborations also extend beyond, working closely with distinguished academic teams at the Universities of Oxford, Cambridge, Edinburgh, Cardiff, London, Glasgow, and the Francis Crick Institute.

 

News from the Centre

We are recruiting a Group Leader in In Vivo Cancer Modelling. We welcome applications at both the Career Development Faculty and Career Faculty levels. Competitive start up package is available. For further particulars please contact [email protected].

 

 

Current vacancies

There are currently no vacancies available in this group or area.

News from the ICR

08/07/26

Scientists have developed a powerful new gene-editing platform that allows them, for the first time, to systematically test the function of key proteins in mammalian cells.

Using the technology, researchers have created the first comprehensive functional map of key sites on proteins called histones, which act as spools around which DNA is wound. Histones help package the genome and play a crucial role in controlling which genes are switched on or off.  

By revealing which of these key sites are essential for healthy cells, this research – led by scientists at The Institute of Cancer Research, London – could help scientists better understand cancer.

Funding for the research was provided by UK Research and Innovation, the Royal Society and The Institute of Cancer Research (ICR), which is both a research institute and a charity. The findings were published in Nature Genetics.

Overcoming a long-standing obstacle

Small chemical tags attached to histones can alter gene activity, influence cell identity and help maintain genome integrity. Although scientists have identified more than 100 different histone modifications, understanding exactly what many of them do has proven remarkably difficult.

One major obstacle has been the complexity of mammalian genomes. Histone genes exist in many near-identical copies scattered throughout the genome, making it extremely challenging to alter every copy of a specific histone site and observe the consequences. Previous approaches often introduced unintended changes and lacked the precision required for systematic studies.

The new study overcame these limitations. The researchers developed a high-throughput CRISPR prime-editing platform capable of precisely editing all copies of mammalian histone H3 genes in their natural genomic locations. The system allows scientists to introduce targeted mutations, reverse them if required and even combine multiple mutations to investigate how different histone modifications interact.

Discovering which histone sites matter most

To demonstrate the power of the platform, the team systematically altered every lysine residue within histone H3. Lysines are amino acids that frequently carry regulatory chemical modifications, making them key control points for gene activity.

The researchers replaced individual lysines with another amino acid, arginine, preventing the usual chemical modifications from occurring. By comparing these mutant cells with carefully matched control cells, they were able to measure the contribution of each lysine to cell fitness and function.

The experiments revealed a small group of particularly important residues. Mutations affecting H3K4, H3K9, H3K14, H3K18 and H3K79 reduced cellular fitness, suggesting that the normal modifications occurring at these sites are essential for healthy cell growth and survival. Some mutations were so poorly tolerated that researchers struggled to create fully edited cell lines because cells carrying too many mutations were outcompeted by healthier cells.

In contrast, mutations at several other lysine sites had little effect on cellular fitness under the conditions tested. This suggests that histone H3 lysines make different contributions to cell function and that some may play roles in specific biological contexts that were not captured in this study. Together, the findings provide one of the clearest pictures so far of how individual histone H3 residues contribute to mammalian cell function.

The platform also allowed the researchers to study combinations of mutations. They found that some pairs of mutations had much stronger effects than either mutation alone. In particular, simultaneous mutations at positions H3K27 and H3K36 impaired stem-cell self-renewal and altered patterns of gene expression, revealing previously hidden interactions between chromatin-regulating pathways.

One of the study's notable findings involved H3K56, a histone site previously linked to DNA damage responses in yeast and fruit flies. The researchers showed that mammalian cells carrying H3K56 mutations were more sensitive to DNA damage, providing evidence that this genome-protective function has been conserved through evolution.

Laying the foundations for future cancer research

First author Daniel Price, Higher Scientific Officer at the ICR, said: “Our study establishes a scalable framework for functional interrogation of histone alterations in mammalian cells.

“The work is fundamentally a basic-science advance rather than a medical breakthrough, but the implications could be significant in the long term. Abnormal chromatin regulation is a hallmark of many cancers, and large-scale sequencing studies have identified recurrent mutations in histones and chromatin-regulating proteins across numerous tumour types.

“Although the clinical impact is not immediate, the technology provides a powerful new way to investigate how chromatin regulation contributes to cancer and other diseases, which may eventually inform future treatments.”

Senior author Dr Alex Radzisheuskaya, Group Leader of the Chromatin Biology Group at the ICR, said: “Our findings provide an unprecedented view of the histone residues that regulate mammalian genomes, and they offer researchers a powerful new toolkit for decoding the biology of chromatin.

“By finally making it possible to systematically test the function of individual histone residues, we have opened the door to a deeper understanding of how cells maintain their identity and protect their DNA, as well as how these processes go wrong in diseases such as cancer.

“We hope that both the methodology and the collection of precisely engineered cell lines generated during this project will become a valuable resource for scientists studying gene regulation, genome stability, development, cancer and epigenetic therapies.”

Image credit:  Anja from Pixabay (modified)